Extension Application for Xeomin(R) for the New Indication Spasticity was
Approved in Various European Countries
This important extension of indication is based on the Kanovsky study, the largest randomized, placebo-controlled, double-blind trial with a botulinum toxin in upper limb post-stroke spasticity to date.
Worldwide, an estimated 12 million people are affected by spasticity, the majority of cases resulting from stroke. Aside from the pain and significant discomfort, post-stroke spasticity can negatively influence mobility, the ability to carry out personal hygiene, and other activities of daily living.
About Xeomin®:
Xeomin® is a botulinum neurotoxin type A free from complexing proteins and currently approved in various European countries for the symptomatic treatment of blepharospasm and cervical dystonia of a predominantly rotational form (spasmodic torticollis) in adults.
Merz Pharmaceuticals GmbH (www.merz.com):
Merz Pharmaceuticals, a member of the Merz Group of companies, is an innovative and international healthcare company specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. Merz is a leader in the field of neurology and has developed Xeomin®, a botulinum neurotoxin type A free from complexing proteins, as well as memantine (Axura®/Akatinol®), the first drug for the treatment of moderate to severe Alzheimer's disease. Other franchises covered by Merz are hepatology / metabolic diseases and dermatology.
For further information: Dawn Sciortino, +1-212-537-9495 Web Site: http://www.merz.com
Share this article